Galanin, galanin receptor subtypes and depression-like behaviour.
The pathophysiology of depression remains unclear, but involves disturbances in brain monoaminergic transmission. Current antidepressant drugs, which act by enhancing this type of transmission, have limited therapeutic efficacy in a number of patients, and not rarely serious side-effects. Increasing evidence suggests that neuropeptides, including galanin, can be of relevance in mood disorders. Galanin is coexpressed with and modulates noradrenaline and serotonin systems, both implicated in depression. Pharmacological and genetic studies have suggested a role for galanin in depression-like behaviour in rodents, whereby the receptor subtype involved appears to play an important role. Thus, stimulation of GalR1 and/or GalR3 receptors results in depression-like phenotype, while activation of the GalR2 receptor attenuates depression-like behaviour. These findings suggest that galanin receptor subtypes represent targets for development of novel antidepressant drugs.
Kuteeva
E
E
Department of Neuroscience, Karolinska Institutet, Retzius väg. 8, S-17177 Stockholm, Sweden.
Hökfelt
T
T
Wardi
T
T
Ogren
S O
SO
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001522:Behavior, Animal; D015306:Biogenic Monoamines / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology*; D019004:Galanin / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D051379:Mice; D009479:Neuropeptides / Q000037:antagonists & inhibitors; D051381:Rats; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism; D044088:Receptors, Galanin / Q000145:classification / Q000378:metabolism / Q000502:physiology*
D000928:Antidepressive Agents; D015306:Biogenic Monoamines; D009479:Neuropeptides; D044088:Receptors, Galanin; D044282:Receptor, Serotonin, 5-HT1A; D019004:Galanin